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A B S T R A C T
The Interleukin-23 signalling pathway is important for the differentiation of TH17 lymphocytes and is involved in
the pathogenesis of Inflammatory bowel disease. Polymorphisms in the IL-23 receptor gene were previously found to be
associated with Inflammatory bowel disease in various populations. The aim of this study was to determine whether the
specific rs11209026 and rs7530511 single-nucleotide polymorphisms in the Interleukin-23 receptor gene are associated
with Crohn’s disease and ulcerative colitis in a Croatian patient population. A total of 50 patients with Crohn’s disease
and 93 patients with ulcerative colitis, as well as 99 healthy control subjects were included in the study. The results deter-
mined a significantly higher occurrence of rs11209026 in control group compared to patients with inflammatory bowel
disease, suggesting a protective effect of this polymorphism. The rs11209026 variant was strongly associated with Crohn’s
disease, but it was absent in ulcerative colitis. However, there was no significant association between the rs7530511 poly-
morphism with either ulcerative colitis or Crohn’s disease. Associations presented in this study give potentially impor-
tant insight into the roles of specific Interleukin-23 receptor polymorphisms in Crohn’s disease pathogenesis in the Cro-
atian population.
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Introduction
Inflammatory bowel diseases (IBD) are chronic idio-
pathic inflammatory disorders of the gastrointestinal
tract characterized by variable disease course with epi-
sodes of clinical activity as a result of active inflamma-
tion. The major phenotypes are Crohn’s diseae (CD) and
ulcerative colitis (UC) with IBD having a large spectrum
of clinical presentations with different course and prog-
nosis1,2. IBDs are multifactorial, polygenic diseases with
genetic heterogenicity. Besides genetic predisposition, a
number of host (epithelial, immune, nonimmune...) and
environmental factors play major roles in the patho-
genesis of IBD3. It is becoming more clear that IBD is a
result of an inappropriate inflammatory response to in-
testinal microbes in a genetically susceptible host3. Nu-
merous genetic studies highlighted the importance of
host-microbe interactions and among the identified ge-
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netic factors, nucleotide oligomerization domain 2 (NOD2),
autophagy genes and components of the interleukin-
-23-type 17 helper T-cell (Th17) pathway play major roles
in perpetuating the abnormal inflammatory response in
IBD3. The strong genetic component as a major factor is
illustrated in the fact that the lifetime risk to develop CD
is about 10–20% in the presence of an affected first-de-
gree relative4–6. Defining subgroups based on genetic mu-
tations might therefore be a helpful marker, especially
when planning personalized therapy in the future4.
The interleukin-23 signalling pathway is recognized
as a very important pathogenetic mechanism in IBD.
Interleukin-23 is a pro-inflammatory cytokine belonging
to the interleukin-12 cytokine family and is essential for
the differentiation of Th17 lymphocytes – a subtype of T
lymphocytes implicated in chronic inflammatory/autoim-
mune diseases7. Therefore, this pathway is considered an
important therapeutic target and the monoclonal anti-
body Ustekinumab was developed to target the common
p40 subunit of interleukin-23 and interleukin-12 (and
currently licensed for psoriasis treatment)7.
Duerr and co-workers identified, in a genome-wide as-
sociation study, the interleukin-23 receptor (IL23R) gene
on chromosome 1p31 as an IBD gene. This gene encodes
a subunit of the receptor for the proinflammatory cyto-
kine interleukin-238. Furthermore, they found that the
uncommon single-nucleotide polymorphism (SNP) cod-
ing variant rs11209026 (c.1142G>A, p.Arg381Gln) is as-
sociated with protection against CD in both Jewish and
non-Jewish populations. Additional noncoding IL23R va-
riants were independently associated8. Replication stud-
ies confirmed IL23R associations in independent cohorts
of patients with CD or UC8. The rs11209026 SNP in
IL23R gene had a protective effect for IBD in a Dutch
case-control analysis9 and both UC and CD were associ-
ated with IL23R9. Subsequently, among other studies, a
German study confirmed the rs11209026 association to
CD also in children IBD population, verifying a protec-
tive effect of the rs11209026 SNP for CD, but not for
UC10. The rs11209026 SNP is part of a haplotype with
rs7530511 that is associated with psoriasis11 and
psoriatic arthritis12, but also with several other immune-
-pathological conditions including ankylosing spondylitis
in Hungarian population samples13.
The aim of this work was to determine whether spe-
cific SNPs rs11209026 and rs7530511 in the IL23R gene
are linked to CD and/or UC in a Croatian IBD patient
population. The research is crucial for gaining more in-
sight into pathogenetic mechanisms of IBD in the Cro-
atian population, as well as for optimization and efficient
use of future therapies specifically targeting the IL-23
signalling pathway.
Materials and Methods
Patients
A total of 50 patients with CD (26 males, median age
35 yr, interquartile range 21–40 yr), 93 patients with UC
(52 males, 47 (36–59) yr) and 99 ethnically and geograph-
ically matched healthy control subjects (84 males, 36
(26–47) yr) were included in the study. All were adults,
Caucasian and living in eastern Croatia. Diagnosis of
IBD (CD or UC) was established according to standard
clinical criteria, including endoscopic, radiological and
histopathological analysis at the University Hospital
Centre Osijek, Croatia. Median follow-up for the entire
cohort of IBD patients was six (interquartile range 3–12)
years. The institutional ethical committee approved the
study and all participants gave informed consent before
testing.
SNP determination
The specific rs11209026 and rs7530511 SNPs of the
IL23R gene were determined in the IBD patient group
and in the healthy control group. Genomic DNA was ex-
tracted from 200 mL EDTA treated blood with High Pure
PCR Template Preparation Kit (Roche Diagnostics,
Mannheim, Germany) according to manufacturer’s in-
structions. Genotyping was done with primers obtained
from TIBMOLBIOL (Berlin, Germany) and LightCycler
FastStart DNA Master SYBR Green Kit purchased from
Roche Diagnostics, Mannheim, Germany in a Light-
Cycler System (Roche Diagnostics Mannheim, Germany)
with subsequent fluorescent probe melting point analy-
sis. For the SNP IL-23R rs11209026 detection, a master
mix contained 2 mM MgCl2, 0.5 mM of the primers
5´-CCT TCC TTT CAT TAG ACA ACA GAG G-3´ and
5´-AAC TGA AAT GAC TAA ATT TTG GTG A-3´, and
0.2 mM of the probes: 5/-ACA GAT CAT TCC AAA cTG
GGT-FL and LC640-GTT TTT GCA GAA TTT CTG TTT
TCT GAT TT-PH, and 2 mL of FastStart (Roche Diagnos-
tics, Mannheim, Germany) mixture. Obtained 194 bp
PCR product was analyzed using melting curve analysis
(54 °C for GG genotype, 54 °C and 61 °C for GA genotype,
and 61 °C for AA genotype). The SNP IL-23R rs7530511
was analyzed by asymmetric PCR. A mastermix con-
tained 2.65 mM MgCl2, 0.9 mM forward (5´-GGA GCC
AAA CAT TAA GTA CGT ATT T-3´) primer, 0.7 mM re-
verse (5´-CCT GCT TCc GGT GCT TTA TGA- 3´) and
0.2 mM hybridization probes 5´-AGG CAA AAG GTA
CTG GCA GCC-FL and LC640-TGG AGT TCA CCG
TTT TTT CA-PH. Amplified 105 bp PCR product was
analyzed using melting curve analysis (63 °C for TT ge-
notype, 53 °C and 63 °C for TC genotype, and 53 °C for
CC genotype). To prevent genotyping errors DNA sam-
ples were genotyped in duplicate by RealTime PCR based
method.
Statistical methods and analysis
Data are presented as medians with interquartile
ranges (IQR), absolute and relative frequencies, depend-
ing on the scale of the measure. Departures from the
Hardy-Weinberg equilibrium were analyzed by using an
exact test14. Single marker effects were assessed simulta-
neously by Westfall-Young permutation procedures15 giv-
ing P-values corrected for multiple testing (10000 repli-
cates, PLINK 1.0716, http://pngu.mgh.harvard.edu/pur-
S. Mihaljevi} et al.: Polymorphisms of IL23R and IBD, Coll. Antropol. 37 (2013) 4: 1171–1177
1172
cell/plink). Permutation-corrected P-values of <0.05 were
taken as significant. Odds ratios (OR) and median unbi-
ased estimates (MUE)17 with their respective 95% confi-
dence intervals (CI) were used to measure the strength of
association (LogXAct 10, Cytel Inc., Cambridge, MA,
USA).
Power calculations were performed using the Genetic
Power Calculator program (http://pngu.mgh.harvard.
edu/~purcell/gpc). Assuming a multiplicative model, a
two-tailed type I error rate of a=0.05 and a population
disease prevalence of 0.005, the sample size employed in
this study was sufficient to give 80% power to detect as
significant an odds ratio of 2.6, 2.1 and 1.65 for 5, 10 and
35% minor allele frequency in the control population.
Results
All genotype distributions were in Hardy-Weinberg
equilibrium (Table 1). The observed population allele fre-
quencies in controls were similar to those reported in
other Caucasian populations18. In the combined popula-
tion (IBD, UC+CD), the rs11209026 A allele was differ-
entially distributed between cases and controls (2.1 vs.
7.1%, p=0.014, Table 1), indicating a significant reduc-
tion in IBD risk for carriers (allelic OR 0.28; 95% CI
0.11–0.75). With respect to each of the populations, the
prevalence of the uncommon rs11209026 p.381Gln vari-
ant was lower in CD, but not UC patients compared to
healthy controls, suggesting a protective effect against
CD (Table 2). The rs7530511 variant, in contrast, was as-
sociated neither with CD nor with UC.
The genotype distributions of the rs11209026 and
rs7530511 variant in the IL23R gene are shown in Table
3 and Table 4. For the rs11209026 SNP, a significantly re-
duced risk of IBD (OR 0.27, 95% CI 0.1–0.72), limited
most likely to the CD phenotype only (MUE 0.09, 95% CI
0–0.54), was observed for heterozygous A/G carriers as
compared with the homozygous G/G genotype (Table 3).
No minor allele homozygotes or heterozygotes were ob-
served for CD cases, nor were rare AA homozygotes ob-
served in any other study group. For the rs753051 SNP,
no significant effect on disease susceptibility was ob-
served. The IL23R variants did not influence the age at
diagnosis (data not shown).
Discussion
The results presented in this work associate the rs
11209026 SNP (minor allele A) in the IL23R gene with
CD in the manner that the SNP represents a protective
factor for CD development. It is impressive that no case
of CD was found to have the rs11209026 SNP. The GA ge-
notype was found to be relevant in this link with CD pro-
tection. On the other hand, there was no such association
of this SNP with UC. When all IBD patients are analyzed
together, there is a significant association of rs11209026
with IBD (conferring a protective effect). The rs7530511
SNP of the IL23R was not by itself associated with CD or
UC, and also when all IBD patients were analyzed to-
gether there was no statistically significant link in this
Croatian IBD patient population.
A protective effect of rs11209026 of the IL23R in the
Croatian population is in accordance with previously
published results of other populations where this SNP
was found to be significantly less represented in CD
patients8–10. In some of those other works, there was also
no evident link to UC, reflecting a potential difference in
pathogenetic factors between the two IBD phenotypes,
and this lack of UC-association was confirmed in the Cro-
atian population of this study. Interestingly, some stud-
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TABLE 1
ALLELIC COMPARISONS BETWEEN IBD (CASE) AND HEALTHY (CONTROL) POPULATIONS FOR THE IL23R SNPS
SNP
Minor
allele
Case Control OR (95% CI) p*
HWE
controls p
HWp
IL23R rs11209026 A 0.021 0.071 0.28 (0.11–0.75) 0.014 1 1
IL23R rs7530511 T 0.105 0.101 1.04 (0.57–1.9) 1 0.054 0.727
OR – Odds ratio, CI – confidence interval, HWE – Hardy-Weinberg equilibrium, * – Empirical p-value, 104 permutations, Westfall-
-Young correction
TABLE 2
ALLELIC COMPARISONS BETWEEN IBD (CASE) AND HEALTHY (CONTROL) POPULATIONS FOR THE IL23R SNPS, SEPARATED BY
DISEASE (CD AND UC)
Disease SNP Minor allele Case Control OR (95% CI) p*
CD
IL23R rs11209026 A 0 0.071 0.09 (0–0.57)** 0.013
IL23R rs7530511 T 0.12 0.101 1.21 (0.57–2.6) 0.871
UC
IL23R rs11209026 A 0.032 0.071 0.44 (0.16–1.17) 0.185
IL23R rs7530511 T 0.097 0.101 0.95 (0.49–1.87) 1
OR – Odds ratio, CI – confidence interval, * – Empirical p-value, 104 permutations, Westfall-Young correction, ** – median unbiased es-
timate
ies, including the work of Büning and coworkers19 found
that the rs11209026 variant of the IL23R confers a pro-
tective effect not only against CD, but also against UC.
Such a protective effect for UC alone was not evident in
our Croatian cohort, based on the presented results.
There was, however, not enough statistical power to con-
firm an effect of such a proportion in a sample of this
size.
Although the ultimate goal of such research investi-
gating genetic susceptibility to certain chronic diseases is
to foster personalized medicine in which an individual
genetic profile would help direct further diagnostic work-
up and optimize therapy, the realistic clinical utility of
the presently known genetic associations remains un-
clear. A large French case-control study by Jung and
co-workers looked into 53 CD-associated genetic poly-
morphisms of 798 CD patients from referring paediatric
and adult gastroenterology centres, linking predomi-
nantly NOD2 variants with CD, but also accentuating
some significant associations with rs11209026 of the
IL23R gene20. The patient population in that study in-
cluded cases of most severe CD comparable to subjects in
our study, included at a tertiary clinical center where the
most severe IBD cases are followed up. The authors con-
cluded, however, that it cannot be recommended to
genotype the studied polymorphisms in routine practice
because the interpretation of the number, nature and
strength of the associations did not argue for their use-
fulness in clinical practice20.
A number of other studies looked into the link be-
tween IL23R polymorphisms and IBD in various popula-
tions. Weersma et al. confirmed the association of the
rs11209026 SNP with CD in a Dutch-Belgian cohort, but
also found associations with a number of other polymor-
phisms21. An association of rs11209026 with CD was con-
firmed in the Czech population by Dusatkova and cowor-
kers22, in Spanish populations by Oliver et al.23 and
Marquez et al.24, in a German population by Glas et al.25,
in New Zealand Caucasians by Roberts et al.26, in a Bra-
zilian population by Baptista et al.27, in a Hungarian pop-
ulation by Lakatos28 and in a British cohort by Cotterill
et al.29. On the contrary, Venegas et al. researching a
Chilean cohort of a similar size as the one investigated in
our study found no association of the rs11209026 SNP of
the IL23R with either CD or UC. The polymorphism was
present in about 5.2% of the control group and 5% of IBD
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TABLE 4
GENOTYPE ASSOCIATIONS
SNP Genotype Case N (%) Control N (%) p* OR (95% CI)
IL-23R rs11209026
AA 0 0
0.015
–
GA 6 (4.2) 14 (14.1) 0.27 (0.1–0.72)**
GG 137 (95.8) 85 (85.9) 1***
IL–23R rs7530511
TT 0 3 (3.1)
0.128
0.19 (0–1.8)**
CT 30 (21) 14 (14.1) 1.56 (0.78–3.12)
CC 113 (79) 82 (82.8) 1***
OR – odds ratio, CI – confidence interval, N – number of subjects, * – Empirical p-value, 104 permutations, Westfall-Young correction
** – median unbiased estimate, *** – reference genotype
TABLE 3
COMPARISON OF IL23R SNPS BY GENOTYPE AND SEPARATED BY DISEASE (CD AND UC)
Disease SNP Genotype Case N (%) Control N (%) p* OR (95% CI)
CD
IL23R rs11209026
AA 0 0
0.012
–
GA 0 14 (14.1) 0.09 (0–0.54)**
GG 50 (100) 85 (85.9) 1***
IL23R rs7530511
TT 0 3 (3.1)
0.38
0.57 (0–5.43)
CT 12 (24) 14 (14.1) 1.85 (0.78–4.38)
CC 38 (76) 82 (82.8) 1***
UC
IL23R rs11209026
AA 0 0
0.288
–
GA 6 (6.5) 14 (14.1) 0.42 (0.15–1.14)
GG 87 (93.5) 85 (85.9) 1***
IL23R rs7530511
TT 0 3 (3.1)
0.381
0.29 (0–2.73)
CT 18 (19.4) 14 (14.1) 1.41 (0.65–3.02)
CC 75 (80.6) 82 (82.8) 1***
OR – Odds ratio, CI – confidence interval, N – number of subjects, * – Empirical p-value, 104 permutations, Westfall-Young correction,
** – median unbiased estimate, *** – reference genotype
patients (7.9% for CD and 3.2% for UC)30. This lack of
rs11209026 involvement in the genetic predisposition to
IBD in this Chilean population highlights ethnic differ-
ences in the genetic background of IBD30 and raises the
need to explore such associations in various populations
to draw a complete picture about IBD predisposition and
pathogenesis. A study of polymorphisms in Lithuanian
IBD patients found as well no association between rs
11209026 and either CD or UC31.
Besides such discussed cohort studies, there were sev-
eral large meta-analyses determining associations of
IL23R variants with IBD. These meta-analyses should be
accentuated, because the differences found in small co-
hort studies may reflect differences in statistical power
due to small sample sizes, imbalances in allelic links,
allelic frequency differences or differences in the compo-
sition of recruited subject groups. Meta-analysis con-
ducted by Li et al. supported the polymorphisms rs
11209026 and rs7517847 within the IL23R gene as pro-
tective factors against developing CD32. But the authors
concluded that further case-control studies especially
concerning ethnicity differences should be performed to
clarify possible roles of IL-23R in CD32. The presented
case-control study on a Croatian IBD patient population
is an example of the necessary additional research. A
meta-analysis by Cotterill et al. on 13,000 cases provided
more strong evidence that the rs11209026 polymorphism
alters susceptibility to CD across populations of Euro-
pean ancestry29.
There are also other immune-related diseases with an
association to rs11209026, including ankylosing spondy-
litis33, chronic sarcoidosis34, rheumatoid arthritis35, pso-
riasis36 and systemic sclerosis37. The rs7530511 polymor-
phism was also linked to some of those immune-related
conditions, such as psoriasis38 and psoriatic arthritis39, as
well as ankylosing spondylitis40. The rs7530511 is part of
a haplotype with rs11209026, but Szabo et al. found evi-
dence for the need of haplotype analysis instead of just
single standing SNP analysis when susceptibility to or
protection against a disease is investigated41. The rs
7530511 SNP could certainly be a potentially interesting
research target. However, there is a lack of studies con-
firming a link of rs7530511 to CD or UC, and our results
did not find such an association either.
The IL-23 signalling pathway and its importance for
the differentiation of TH17 lymphocytes is becoming
more and more clearly implicated in various autoim-
mune and chronic inflammatory diseases and is also rec-
ognized as an important pathogenetic pathway in IBD7.
The molecular location of the IL23R gene is on chromo-
some 1. The receptor IL23R, consisting of an IL-12b1 and
an IL-23R chain, is highly expressed on the cell mem-
brane of memory T cells and other immune cells, such as
natural killer cells, monocytes, and dendritic cells and in-
teracts with IL-2342. It is involved in the mediation of
proinflammatory activities by the production of IL-17 via
the activation of Th17 lymphocytes, and the role of this
axis in CD pathogenesis was supported in human pa-
tients and animal models of colitis42. It makes it there-
fore an interesting subject for better understanding of
the underlying pathologic processes in IBD and certainly
is becoming a valid therapeutic target. One of the first
drugs specifically targeting IL23R is Ustekinumab, a
monoclonal antibody for the common p40 subunit of
interleukin-23 and interleukin-127. It is already recog-
nized as an effective future treatment option for psoria-
sis7, and trials are under way to test its efficacy in CD.
The efficacy of treatments targeting the IL-23 signalling
system in psoriasis is also interesting in the context of
the previously discussed links of rs11209026 and rs
7530511 to psoriasis. In context of IBD, the rs11209026
of the IL23R could be exploited to define clinical out-
comes, such as a pharmacological approach to mimic the
rs11209026 polymorphism42. In general, the prospect of
diagnostic and therapeutic personalization based on indi-
vidual genetic profiles seems feasible, but further trans-
lational research and abundant replication studies are
needed to extend pioneering findings into clinical prac-
tice43,44.
In conclusion, current clinical usefulness of genetic
associations with IBD as discussed here and investigated
in this work is at the present somewhat limited, further
research is necessary to make final judgements about
possible individualized diagnostic approaches. To the
best of our knowledge, this is the first study exploring
the specific IL23R SNPs in a Croatian IBD patient popu-
lation and broadens the insight into genetic implications
of IBD pathogenesis in the Croatian population. Perhaps
with a combined future use of multiple genetic markers,
where IL23R variants would be interpreted in context of
several other significant markers, a potential diagnostic
or therapeutic benefit could become apparent. Since spe-
cific therapies targeting the IL-23 signalling pathway are
on the verge of clinical use in IBD (such as Ustekinu-
mab), investigation of the IL-23 signalling components in
Croatian IBD patients is interesting and might provide
useful information for more efficient treatment choices
in the future.
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POLIMORFIZMI INTERLEUKIN-23 RECEPTORA U PACIJENATA S UPALNIM BOLESTIMA
CRIJEVA U HRVATSKOM TERCIJARNOM CENTRU
S A @ E T A K
Interleukin-23 signalni put je va`an u diferencijaciji TH17 limfocita i uklju~en je u patogenezu upalnih bolesti crije-
va. Polimorfizmi interleukin-23 receptora u ranijim istra`ivanjima povezivani su s upalnim bolestima crijeva u razli-
~itim populacijama. Cilj ovog istra`ivanja bio je odrediti povezanost specifinih rs11209026 i rs7530511 polimorfizama
pojedina~nog nukleotida (eng. single nucleotide polymorphism) interleukin-23 receptora s Crohnovom bole{}u i ulce-
roznim kolitisom u hrvatskoj populaciji pacijenata tercijarnog klini~kog centra. Ukupno 50 pacijenata s Crohnovom
bole{}u i 93 pacijenta s ulceroznim kolitisom, kao i 99 zdravih kontrolnih ispitanika uklju~eno je prospektivno. Rezul-
tati ukazuju na zna~ajno ve}u pojavnost rs11209026 polimorfizma u zdravih ispitanika u odnosu na pacijente s upalnim
bolestima crijeva, {to sugerira protektivan u~inak ovog polimorfizma. Kada se analiziraju posebno pacijenti s Crohno-
vom bole{}u i s ulceroznim kolitisom, povezanost je bila zna~ajna za Crohnovu bolest, ali odsutna za ulcerozni kolitis.
rs7530511 polimorfizam, me|utim, nije bio zna~ajno povezan niti s Crohnovom bole{}u niti s ulceroznim kolitisom.
Povezanosti s polimorfizmima prikazane u ovom istra`ivanju predstavljaju potencijalno va`an uvid u uloge polimor-
fizama interleukin-23 receptora u patogenezi Crohnove bolesti u hrvatskoj populaciji.
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